Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Brukinsa® (zanubrutinib) – New indication
January 19, 2023 - BeiGene announced the FDA approval of Brukinsa (zanubrutinib), for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
